A double-blind placebo-controlled trial of granulocyte colony-stimulating factor in elderly patients with previously untreated acute myeloid leukemia: a Southwest oncology group study (9031).
about
Use of glycosylated recombinant human G-CSF (lenograstim) during and/or after induction chemotherapy in patients 61 years of age and older with acute myeloid leukemia: final results of AML-13, a randomized phase-3 studyTimed sequential chemotherapy with concomitant granulocyte colony-stimulating factor for high-risk acute myelogenous leukemia: a single arm clinical trialSequential phase II Southwest Oncology Group studies (S0112 and S0301) of daunorubicin and cytarabine by continuous infusion, without and with ciclosporin, in older patients with previously untreated acute myeloid leukaemiaA single dose of pegfilgrastim compared with daily filgrastim for supporting neutrophil recovery in patients treated for low-to-intermediate risk acute myeloid leukemia: results from a randomized, double-blind, phase 2 trialLow-dose interleukin-2 immunotherapy does not improve outcome of patients age 60 years and older with acute myeloid leukemia in first complete remission: Cancer and Leukemia Group B Study 9720.Dynamics and management of cytopenias associated with dasatinib therapy in patients with chronic myeloid leukemia in chronic phase after imatinib failure.Clinical characteristics and treatment outcome of acute myeloid leukemia in elderly patients in Korea: a retrospective analysisA phase I dose escalation study of oral bexarotene in combination with intravenous decitabine in patients with AML.Nonmyeloablative allogeneic hematopoietic cell transplantation in patients with acute myeloid leukemia.Treatment options in Invasive Aspergillosis.Age and acute myeloid leukemia.Time from diagnosis to treatment initiation predicts survival in younger, but not older, acute myeloid leukemia patientsXPD DNA nucleotide excision repair gene polymorphisms associated with DNA repair deficiency predict better treatment outcomes in secondary acute myeloid leukemia.The prognostic significance of IRF8 transcripts in adult patients with acute myeloid leukemiaMesenchymal stem cell therapy for acute radiation syndrome: innovative medical approaches in military medicinePrognostic significance of NPM1 mutations in the absence of FLT3-internal tandem duplication in older patients with acute myeloid leukemia: a SWOG and UK National Cancer Research Institute/Medical Research Council report.Cell signaling-based classifier predicts response to induction therapy in elderly patients with acute myeloid leukemiaPrognostic implications of the IDH1 synonymous SNP rs11554137 in pediatric and adult AML: a report from the Children's Oncology Group and SWOGA phase 2 study of the farnesyltransferase inhibitor tipifarnib in poor-risk and elderly patients with previously untreated acute myelogenous leukemiaMutations in the DNMT3A exon 23 independently predict poor outcome in older patients with acute myeloid leukemia: a SWOG report.Gene expression profiling of adult acute myeloid leukemia identifies novel biologic clusters for risk classification and outcome prediction.Effects of granulocyte-colony stimulating factor and the expression of its receptor on various malignant cellsClofarabine with high dose cytarabine and granulocyte colony-stimulating factor (G-CSF) priming for relapsed and refractory acute myeloid leukaemiaRapid induction of complete molecular remission by sequential therapy with LDAC and sorafenib in FLT3-ITD-positive patients unfit for intensive treatment: two cases and review of the literaturePrognostic impact of monosomal karyotype in young adult and elderly acute myeloid leukemia: the Southwest Oncology Group (SWOG) experienceVery late antigen-4 function of myeloblasts correlates with improved overall survival for patients with acute myeloid leukemia.Prediction of CR following a second course of '7+3' in patients with newly diagnosed acute myeloid leukemia not in CR after a first course.Targeted treatment of acute myeloid leukemia in older adults: role of gemtuzumab ozogamicin.A phase 2 trial of azacitidine and gemtuzumab ozogamicin therapy in older patients with acute myeloid leukemia.Clinical management of primary non-acute promyelocytic leukemia acute myeloid leukemia: Practice Guidelines by the Italian Society of Hematology, the Italian Society of Experimental Hematology, and the Italian Group for Bone Marrow Transplantation.What is the impact of hematopoietic cell transplantation (HCT) for older adults with acute myeloid leukemia (AML)?Decitabine as a First-Line Treatment for Older Adults Newly Diagnosed with Acute Myeloid Leukemia.Comparison of survival outcomes among cancer patients treated in and out of clinical trials.Treatment of older patients with acute myeloid leukemia (AML): a Canadian consensusConcise review: next-generation cell therapies to prevent infections in neutropenic patients.A model for prediction of FLT3-ITD and NPM1 (without FLT3-ITD) positivity in patients with newly diagnosed acute myeloid leukaemia.A systematic literature review of the efficacy, effectiveness, and safety of filgrastim.Impact of Specimen Heterogeneity on Biomarkers in Repository Samples from Patients with Acute Myeloid Leukemia: A SWOG Report.
P2860
Q24670020-FA600C3B-C61A-45AA-B3C4-0AD9A5B3BB54Q24792014-2FB7489D-6AD9-49E7-9490-3B87F01D6305Q30497200-608696DC-8729-4B10-8C71-C2491E86264BQ33350688-99C5D9C5-CC16-4D27-BD85-6A856A237DFFQ33380148-49CA6665-9844-4902-916C-3D2BCC3B503CQ33384955-EA138564-596F-43FB-A0D8-A6ADA6FEFA6DQ33875902-592C503D-1B16-43D5-BE37-2211806860D9Q33939624-B3DDA4A5-D8C2-4632-9498-D5FA10D88776Q33990856-CB846020-D685-43CC-8A75-0945DC984B4DQ34357504-D985BEF3-2729-4298-8ED0-1CA6C843B123Q34564663-FCC76212-8593-4024-8FB9-B85B7C3FD179Q34597777-535B3730-DDF7-4FED-BF64-B16AAD9E3B2FQ34629500-0FCA2E65-74E0-4AF8-A4EC-C80FA6524416Q34962889-78F10419-C692-42DD-B3E7-E95347DB639BQ35122122-7F4CDDB2-F37F-427F-A0A9-AFE39D81A0A8Q35215042-63506FAB-B309-4CA2-8952-0C9F41DC3AA2Q35462617-FAE639CE-07FB-486F-85E5-CF9E2835F6FEQ35525313-E4BEF9A4-60E6-4C14-B220-ADC161389FF9Q35628954-E3B40289-20D6-4ABD-BBA5-C0934975CF18Q35687895-16887AC5-691D-40BD-94E9-2139B9B46A30Q35848938-4A7F9082-A3EE-4B4C-B08B-D1B0A6A72565Q36297673-1DC840F6-CAEB-493F-A3A4-61B3B392711CQ36806921-A25D7CE4-6FD3-4345-9950-ACD3D2F7E5F1Q36940606-48B278C1-633D-4BE7-9370-920972BBE496Q37006786-28C9750C-514A-4790-BA1B-2487D5AFB4AAQ37071108-2ECF13B7-E1F6-4808-B77C-58E04DD4F9E4Q37166414-D79D10B4-89FD-4CCF-9DE4-9830E92D512FQ37199950-C3862A92-11D9-4B80-BB03-242ABD35B91EQ37311249-7B43BFDE-1A6C-47CD-A189-12E04564D4F6Q37323006-74501435-EB45-4069-8413-2F0B883FF113Q37337422-FC02457E-12E8-4A61-A01B-272E2A5A357CQ37438385-D6D45901-F139-4ED4-A97C-9CC6AA9F16A1Q37696455-71754B3C-3FB1-4055-9DFE-B0525D244346Q38106983-56B89794-F00A-4CF4-8062-6A7D2146A3F7Q38193653-1E55E42A-587D-467F-AFD7-EEE5CDC5BF9CQ41872131-48554F73-A027-4C40-AF3F-AC199D785B21Q47938059-30F662D0-D55A-405E-A1C6-ED8F66ECACB3Q49668289-90CECACF-0C9D-4835-878C-156B5751FD37
P2860
A double-blind placebo-controlled trial of granulocyte colony-stimulating factor in elderly patients with previously untreated acute myeloid leukemia: a Southwest oncology group study (9031).
description
1998 nî lūn-bûn
@nan
1998 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
1998 թվականի մայիսին հրատարակված գիտական հոդված
@hy
1998年の論文
@ja
1998年論文
@yue
1998年論文
@zh-hant
1998年論文
@zh-hk
1998年論文
@zh-mo
1998年論文
@zh-tw
1998年论文
@wuu
name
A double-blind placebo-control ...... t oncology group study (9031).
@ast
A double-blind placebo-control ...... t oncology group study (9031).
@en
type
label
A double-blind placebo-control ...... t oncology group study (9031).
@ast
A double-blind placebo-control ...... t oncology group study (9031).
@en
prefLabel
A double-blind placebo-control ...... t oncology group study (9031).
@ast
A double-blind placebo-control ...... t oncology group study (9031).
@en
P2093
P1433
P1476
A double-blind placebo-control ...... t oncology group study (9031).
@en
P2093
Balcerzak SP
Kopecky KJ
Willman CL
P304
P407
P577
1998-05-01T00:00:00Z